Furthermore, we demonstrated that there are discrepancies between the amplification status of the primary tumor and the corresponding lymph node metastases, which can be explained by intratumoral heterogeneity of FGFR2-amplified tumor clones. This evidence concerns the gene FGFR2 and neoplasm.